Cargando…
Survival outcomes with oral azacitidine maintenance in patients with acute myeloid leukemia in remission by receipt of initial chemotherapy: subgroup analyses from the phase III QUAZAR AML-001 trial
| Autores principales: | , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Fondazione Ferrata Storti
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10542842/ https://www.ncbi.nlm.nih.gov/pubmed/36951156 http://dx.doi.org/10.3324/haematol.2022.282296 |
| _version_ | 1785114179967909888 |
|---|---|
| author | Wei, Andrew H. Roboz, Gail J. Dombret, Hervé Döhner, Hartmut Schuh, Andre C. Montesinos, Pau Selleslag, Dominik Bondarenko, Sergey N. Prebet, Thomas Lai, Yinzhi Skikne, Barry Beach, C.L. Ravandi, Farhad |
| author_facet | Wei, Andrew H. Roboz, Gail J. Dombret, Hervé Döhner, Hartmut Schuh, Andre C. Montesinos, Pau Selleslag, Dominik Bondarenko, Sergey N. Prebet, Thomas Lai, Yinzhi Skikne, Barry Beach, C.L. Ravandi, Farhad |
| author_sort | Wei, Andrew H. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10542842 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Fondazione Ferrata Storti |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-105428422023-10-03 Survival outcomes with oral azacitidine maintenance in patients with acute myeloid leukemia in remission by receipt of initial chemotherapy: subgroup analyses from the phase III QUAZAR AML-001 trial Wei, Andrew H. Roboz, Gail J. Dombret, Hervé Döhner, Hartmut Schuh, Andre C. Montesinos, Pau Selleslag, Dominik Bondarenko, Sergey N. Prebet, Thomas Lai, Yinzhi Skikne, Barry Beach, C.L. Ravandi, Farhad Haematologica Letter to the Editor Fondazione Ferrata Storti 2023-03-23 /pmc/articles/PMC10542842/ /pubmed/36951156 http://dx.doi.org/10.3324/haematol.2022.282296 Text en Copyright© 2023 Ferrata Storti Foundation https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited. |
| spellingShingle | Letter to the Editor Wei, Andrew H. Roboz, Gail J. Dombret, Hervé Döhner, Hartmut Schuh, Andre C. Montesinos, Pau Selleslag, Dominik Bondarenko, Sergey N. Prebet, Thomas Lai, Yinzhi Skikne, Barry Beach, C.L. Ravandi, Farhad Survival outcomes with oral azacitidine maintenance in patients with acute myeloid leukemia in remission by receipt of initial chemotherapy: subgroup analyses from the phase III QUAZAR AML-001 trial |
| title | Survival outcomes with oral azacitidine maintenance in patients with acute myeloid leukemia in remission by receipt of initial chemotherapy: subgroup analyses from the phase III QUAZAR AML-001 trial |
| title_full | Survival outcomes with oral azacitidine maintenance in patients with acute myeloid leukemia in remission by receipt of initial chemotherapy: subgroup analyses from the phase III QUAZAR AML-001 trial |
| title_fullStr | Survival outcomes with oral azacitidine maintenance in patients with acute myeloid leukemia in remission by receipt of initial chemotherapy: subgroup analyses from the phase III QUAZAR AML-001 trial |
| title_full_unstemmed | Survival outcomes with oral azacitidine maintenance in patients with acute myeloid leukemia in remission by receipt of initial chemotherapy: subgroup analyses from the phase III QUAZAR AML-001 trial |
| title_short | Survival outcomes with oral azacitidine maintenance in patients with acute myeloid leukemia in remission by receipt of initial chemotherapy: subgroup analyses from the phase III QUAZAR AML-001 trial |
| title_sort | survival outcomes with oral azacitidine maintenance in patients with acute myeloid leukemia in remission by receipt of initial chemotherapy: subgroup analyses from the phase iii quazar aml-001 trial |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10542842/ https://www.ncbi.nlm.nih.gov/pubmed/36951156 http://dx.doi.org/10.3324/haematol.2022.282296 |
| work_keys_str_mv | AT weiandrewh survivaloutcomeswithoralazacitidinemaintenanceinpatientswithacutemyeloidleukemiainremissionbyreceiptofinitialchemotherapysubgroupanalysesfromthephaseiiiquazaraml001trial AT robozgailj survivaloutcomeswithoralazacitidinemaintenanceinpatientswithacutemyeloidleukemiainremissionbyreceiptofinitialchemotherapysubgroupanalysesfromthephaseiiiquazaraml001trial AT dombretherve survivaloutcomeswithoralazacitidinemaintenanceinpatientswithacutemyeloidleukemiainremissionbyreceiptofinitialchemotherapysubgroupanalysesfromthephaseiiiquazaraml001trial AT dohnerhartmut survivaloutcomeswithoralazacitidinemaintenanceinpatientswithacutemyeloidleukemiainremissionbyreceiptofinitialchemotherapysubgroupanalysesfromthephaseiiiquazaraml001trial AT schuhandrec survivaloutcomeswithoralazacitidinemaintenanceinpatientswithacutemyeloidleukemiainremissionbyreceiptofinitialchemotherapysubgroupanalysesfromthephaseiiiquazaraml001trial AT montesinospau survivaloutcomeswithoralazacitidinemaintenanceinpatientswithacutemyeloidleukemiainremissionbyreceiptofinitialchemotherapysubgroupanalysesfromthephaseiiiquazaraml001trial AT selleslagdominik survivaloutcomeswithoralazacitidinemaintenanceinpatientswithacutemyeloidleukemiainremissionbyreceiptofinitialchemotherapysubgroupanalysesfromthephaseiiiquazaraml001trial AT bondarenkosergeyn survivaloutcomeswithoralazacitidinemaintenanceinpatientswithacutemyeloidleukemiainremissionbyreceiptofinitialchemotherapysubgroupanalysesfromthephaseiiiquazaraml001trial AT prebetthomas survivaloutcomeswithoralazacitidinemaintenanceinpatientswithacutemyeloidleukemiainremissionbyreceiptofinitialchemotherapysubgroupanalysesfromthephaseiiiquazaraml001trial AT laiyinzhi survivaloutcomeswithoralazacitidinemaintenanceinpatientswithacutemyeloidleukemiainremissionbyreceiptofinitialchemotherapysubgroupanalysesfromthephaseiiiquazaraml001trial AT skiknebarry survivaloutcomeswithoralazacitidinemaintenanceinpatientswithacutemyeloidleukemiainremissionbyreceiptofinitialchemotherapysubgroupanalysesfromthephaseiiiquazaraml001trial AT beachcl survivaloutcomeswithoralazacitidinemaintenanceinpatientswithacutemyeloidleukemiainremissionbyreceiptofinitialchemotherapysubgroupanalysesfromthephaseiiiquazaraml001trial AT ravandifarhad survivaloutcomeswithoralazacitidinemaintenanceinpatientswithacutemyeloidleukemiainremissionbyreceiptofinitialchemotherapysubgroupanalysesfromthephaseiiiquazaraml001trial |